Veraxa Biotech (VRXA) said Monday it is collaborating with Ardigen to use artificial intelligence to advance its BiTAC cancer therapy pipeline.

The partnership will initially focus on developing AI tools to identify and prioritize dual-target combinations for Veraxa's bispecific T-cell engagers and antibody-drug conjugates, it said.

The company said its BiTAC platform uses an "AND-gate" approach that activates when two cancer targets are present on the same cell, a strategy designed to reduce off-target toxicity and improve treatment precision.